

DENV2/DENV3 or 4

GTS2SP

	TRBV	CDR3	TRBJ	Freq (%)
2-1680	5-1	CASRLAASYNEQF	2-1	44.19
	9	CASSGPRDRGNEKLF	1-4	32.56
	19	CAS TKFGSGNTIY	1-3	11.63
	6-1	CASRLNRGPGEQY	2-7	11.63

	TRBV	CDR3	TRBJ	Freq (%)
2-0885	4-1	CASSQMTGTGELF	2-2	16.18
	15	CATSRDRGISNYGYT	1-2	8.82
	10-3	CAIRAGTATYGYT	1-2	7.35
	9	CASSGNEQF	2-1	7.35
	11-2	CASSLKGWAYNEQF	2-1	5.88
	15	CATSRERKGTDEAF	1-1	4.41
	10-3	CAISDGAGTETQY	2-5	4.41
	9	CASSAGTGGDQPQH	1-5	2.94
	7-3	CASSPFGSGTGELF	2-2	2.94
	7-2	CASSFTGTGELF	2-2	2.94
	4-1	CASSQSQTYYEQY	2-7	2.94
	10-3	CAISESPTQNTIY	1-3	2.94
	9	CASSGMGDEQF	2-1	2.94
	9	CANPIEGNEQF	2-1	2.94
	9	CASSVGGGLASNEQF	2-1	1.47
	4-1	CASSQDGTIFYEQY	2-7	1.47
	12-5	CASGRTGPPNLWQF	2-1	1.47
	9	CASKSGSDSTDTQY	2-3	1.47
	9	CASSPQTGVDGELF	2-2	1.47
	7-3	CASSALAGGYNEQF	2-1	1.47
	7-3	CASSAPAGGKQF	2-1	1.47
	7-2	CASSFTGVTGELF	2-2	1.47
	9	CASSGTGRNEQF	2-1	1.47
	4-1	CASSGLADYNEQF	2-1	1.47
	9	CASSGIDNEQF	2-1	1.47
	9	CASSGSGTIEQF	2-1	1.47
	6-2/6-3	CASSYSIPDTQY	2-3	1.47
	9	CASSPGTGEQY	2-7	1.47
	9	CASSGEGSLQY	2-4	1.47
	9	CASSAEGAEQF	2-1	1.47
	9	CASSVGDGEQY	2-7	1.47

	TRBV	CDR3	TRBJ	Freq (%)
2-1672	4-1	CASSQRSRDRGAF	1-1	87.18
	6-2/6-3	CASSYTFRDRKETQY	2-5	10.26
	6-2/6-3	CASSYTFRDAKETQY	2-5	1.28
	4-1	CASSQRSRDRGGAF	1-1	1.28

GTS3SP

	TRBV	CDR3	TRBJ	Freq (%)
2-0885	7-3	CASSLSGTDITQY	2-3	20.63
	4-1	CASSQDPGLNEKLF	1-4	19.05
	24-1	CATSDHSTSGRRNEQF	2-1	6.35
	11-2	CASSLGGAGDRSYEQY	2-7	6.35
	20-1	CSPLHRGQGETQY	2-5	4.76
	12-3/12-4	CASSPSQETQY	2-5	4.76
	4-1	CASSQDPGLAGYEQY	2-7	3.17
	3-1	CAS TP SAGLNNEQF	2-1	3.17
	27	CASSDRGSSPLH	1-6	3.17
	11-2	CASSRGQAYEQF	2-1	3.17
	11-2	CASSPSQGDQPQH	1-5	3.17
	11-2	CASRVGQNTTEAF	1-1	3.17
	4-1	CASSQDPGLAGPEQF	2-1	1.59
	28	CASSQYAGINEKLF	1-4	1.59
	11-2	CASSLGGAGADYEQY	2-7	1.59
	4-1	CASSQDPGLNSPLH	1-5	1.59
	3-1	CASSQLAGIVDTQY	2-3	1.59
	27	CASSLVGSKNIQY	2-4	1.59
	11-2	CASSLGGTDYEQY	2-7	1.59
	11-2	CASSLGPSSGELF	2-2	1.59
11-2	CASSLGGTDQPQH	1-5	1.59	
11-2	CASSTGVSYEQY	2-7	1.59	
11-2	CASSLGPDNEQF	2-1	1.59	
11-2	CASSSGPEDEQF	2-1	1.59	

	TRBV	CDR3	TRBJ	Freq (%)
2-1672	12-3/12-4	CASSWPEETQY	2-5	30.16
	7-8	CASSLGGGNQETQY	2-5	17.46
	28	CASSFGLAGVYRY	2-7	11.11
	9	CASSGGAAYEQY	2-7	11.11
	12-3/12-4	CASSPSQDTEAF	1-1	6.35
	12-3/12-4	CASSFLGDTEYEQY	2-7	4.76
	6-6	CASRSPMGQGTGELF	2-2	3.17
	11-2	CASSHGGSGYGYT	1-2	3.17
	11-2	CASSFIQNTTEAF	1-1	3.17
	11-2	CASSLGPDSPLH	1-6	3.17
	12-3/12-4	CASSLGGAGTQETQY	2-5	1.59
	20-1	CSVARGGSDQPQH	1-5	1.59
29-1	CSAINRGDTEAF	1-1	1.59	
11-2	CASSLGPVELEF	2-2	1.59	

Supplementary Figure 4 TRBV and TRBJ usage, CDR3 β amino acid sequence, and clonotype frequency are shown for CD3⁺CD8⁺CD14⁻CD19⁻ HLA-A*11:01-GTS2 or HLA-A*11:01-GTS3/4 tetramer⁺ populations isolated from patients sequentially infected with various combinations of DENV2/3/4. Recurrent clonotypes are highlighted in color. SP, single positive; GTS3, GTS3/4 (blue type).